- Recommendation ID
- DG22/2
- Question
Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) in people whose Crohn's disease is losing response to a TNF-alpha inhibitor. This could be through a prospective study, for local audit, or for submission to a registry. (The IBD Registry is being adapted to receive data on TNF-alpha inhibitor levels and antibodies against TNF-alpha inhibitors).
- Any explanatory notes
(if applicable) None
Source guidance details
- Comes from guidance
- Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits)
- Number
- DG22
- Date issued
- February 2016
Other details
Is this a recommendation for the use of a technology only in the context of research? | No |
Is it a recommendation that suggests collection of data or the establishment of a register? | Yes |
Last Reviewed | 29/02/2016 |